CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies.
Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
儿童血液癌症是儿童常见恶性肿瘤之一。许多病例无法通过强化化疗治愈,亟需新型疗法。由于安全性较好、具有内在细胞毒性且可通过基因修饰增强特异性和杀伤能力,NK细胞有望成为免疫治疗效应细胞。NK细胞可经工程化表达靶向肿瘤特异性抗原的CAR、下调抑制及调节信号、分泌细胞因子,并优化其与小分子衔接剂的相互作用。了解NK细胞生物学是设计可转化至临床的免疫疗法的关键。
Pediatric blood cancers are among the most common malignancies that afflict children. Intensive chemotherapy is not curative in many cases, and novel therapies are urgently needed. NK cells hold promise for use as immunotherapeutic effectors due to their favorable safety profile, intrinsic cytotoxic properties, and potential for genetic modification that can enhance specificity and killing potential.
NK cells can be engineered to express CARs targeting tumor-specific antigens, to downregulate inhibitory and regulatory signals, to secrete cytokine, and to optimize interaction with small molecule engagers. Understanding NK cell biology is key to designing immunotherapy for clinical translation.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。